Previous 10 | Next 10 |
Agenus (AGEN) announces the dosing of the first cancer patient in Phase 1 clinical trial of agenT-797, an allogeneic iNKT cell therapy, through its subsidiary, AgenTus Therapeutics. The Phase 1 trial has been initiated in hematologic cancers, with expansion into solid tumors expected to ...
LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the dosing...
Agenus (AGEN) announces new clinical data on AGEN1181 at the American Association for Cancer Research ((AACR)) Annual Meeting. The company showcased the optimal performance of AGEN1181 in relevant models. The new data are as follows:New partial response in the first melanoma patient treated (...
7 objective responses observed to date in multiple tumor types New responses reported in patients with melanoma and ovarian cancer Benefit seen in patients typically unresponsive to I-O agents LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an imm...
LEXINGTON, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Jennif...
Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year. By definition, this term refers to stocks that trade under $5. Inherently these stocks are very risky and volatile in nature. This can be a good thing or a bad thing, depen...
Q4 2020 results were about as expected, ending with $89 million in cash. FDA filing expected in Q2 2021 for balstilimab. AGEN1181 looks to be superior to Keytruda. For further details see: Agenus A Buy On Coming 2021 Data, FDA Filings
Image source: The Motley Fool. Agenus Inc (NASDAQ: AGEN) Q4 2020 Earnings Call Mar 15, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus Inc (AGEN) Q4 2020 Earnings Call Transcript
Agenus Inc. (AGEN) Q4 2020 Earnings Conference Call March 15, 2020 08:30 AM ET Company Participants Jan Medina - Director of Investor Relations Garo Armen - Chairman & Chief Executive Officer Jennifer Buell - President & Chief Operating Officer Andy Hurley - Chief Commercial Officer C...
Agenus (AGEN) shares rise nearly 5% premarket after the company posted fourth-quarter results that beat Wall Street estimates, helped partly by upfront license fee gained from recent transactions.The company posted fourth-quarter revenue of $31.26M, that beat analysts' est...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...